NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMA
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMA is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMA; Generic name: NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMA; Manufacturer: Mylan Pharmaceuticals Inc..
| Brand name | NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMA |
|---|---|
| Generic name | NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMA |
| Manufacturer | Mylan Pharmaceuticals Inc. |
| Used for | INDICATIONS AND USAGE Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are indicated for the prevention of pregnancy in women who elect to use combined oral contraceptives as a method of contraception. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are indicated for the treatment of moderate acne vulgaris in females, ≥ 15 years of age, who have no known contraindications to combined oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets should be used for the treatment |
| Dosage | DOSAGE AND ADMINISTRATION The tablet blister has been designed to make norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets dosing as easy and as convenient as possible. The tablets are arranged in four rows of seven tablets each, with the days of the week appearing on the tablet blister above the first row of tablets. Note: Each tablet blister has been preprinted with the days of the week, starting with Sunday, to facilitate a Sunday-Start regimen. Six different day |
| Warnings | WARNINGS The use of combined oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity, and diabete |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=054917fa-573b-4b16-a719-ece6c0909656 |